RE: Manchester Confirmation23 Mar 2023 14:18
sounds like our stroke test!
In addition, a programme to develop a pipeline of new genomic technologies will be established, in collaboration with the University of Manchester. The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme will bring together academic, industry and clinical partners from across the region to deliver enhanced genomic diagnostics to prevent stroke; rapid genetic point of care devices to detect genetic changes; and the development of ‘pharmacogenetic passport’ to optimise precision medicines for patients.
Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”